FIELD: pharmacology.SUBSTANCE: invention relates to a compound of the formula(I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the linker L1 is selected independently and represents -CH2-, -NH-, -O- or -S-； R1 is selected independently and is hydrogen, halogen, -C1-3-alkyl, partially or fully halogenated -C1-3-alkyl, -CN, -OH, -O-C1-3-alkyl, -NH2, -NHC1-3-alkyl, -N (C1-3-alkyl) C1-3-alkyl, -C1-3-alkyl-NH2, -C1-3-alkyl-NH-C1-3-alkyl, -C1-3-alkyl-N(C1-3-alkyl)C1-3-alkyl or a 5-membered heteroaryl ring containing 1 to 4 N atoms and 0 to 1 S atom； R1 group contains 0-2 R4 substituents； R2 is selected independently and is halogen, partially or fully halogenated -CH3 or -OCH3； R3 is selected independently and is hydrogen or halogen； R4 is selected independently and is halogen or C1-3-alkyl； A cycle is selected independently and represents phenyl, a 5-6 membered heteroaryl ring containing 1 to 2 N atoms； A cycle contains 0-1 R5 substituent and 0-2 R6substituent； R5 is selected independently and is phenyl； 5-9 membered heteroaryl containing 1 to 2 N atoms and 0 to 1 S or O atom, 5-6 membered cycloalkyl or 5-6 membered heterocycle containing 1 to 2 N atoms, 0 to 1 S or O atoms； R5 contains 0-2 R'6substituents； R6 and R'6 are selected independently and represent -OH, -C1-3-alkyl, -C(O)OH, -C(O)NH2, -NHC(O)H, -NHC(O)C1-3-alkyl, -C1-3-alkyl-NHC(O)H, -C1-3-alkyl-NHC(O)C1-3-alkyl, -NHC(O)OH, -C1-3-alkyl-NHC(O)OH, -NH2, -NHC1-3-alkyl, -N(C1-3-alkyl)C1-3-alkyl, -C1-3-alkyl-NH2, -C1-3-alkyl-NHC1-3-alkyl, -C1-3-alkyl-N(C1-3-alkyl)C1-3-alkyl, -CN, halogen, -S(O)2NH2, a 5-6 membered saturated, unsaturated or partially saturated heterocycle containing 1 to 4 N atoms, 0 to 1 atom S； R6 and R'6 contain 0-2 R7 substituents； R7 is selected independently and is = O, -C1-3-alkyl, -NH2, -NHC1-3-alkyl, -N (C1-3-alkyl) C1-3-alkyl, -C1-3-alkyl-NH2, -C1-3-alkyl-NHC1-3-alkyl, -C1-3-alkyl-N(C1-3-alkyl)C1-3-alkyl, -OH, -OC1-3-alkyl, -C1-3-alkyl-OH, -C1-3-alkyl-O-C
